Custom Search

News

Monday 03 April 2006

Estimating the impact of rituximab on bcl-2-associated resistance to CHOP in elderly patients with diffuse large B-cell lymphoma.

By: Mounier N, Briere J, Gisselbrecht C, Reyes F, Gaulard P, Coiffier B.

Haematologica 2006 Apr 3; [Epub ahead of print]

Rituximab plus CHOP (R-CHOP) has been proven to increase overall survival in aggressive bcl-2-positive lymphoma patients. Using competing risk analysis, we studied the long-term impact of this treatment in patients from a GELA trial: RCHOP prevented from progression or relapse in both bcl-2-positive and bcl-2-negative patients without increasing the risk of death in complete remission.

Use of this site is subject to the following terms of use